This is because the Congressional Budget Office (CBO), Congresss official scorekeeper for proposed legislation, would incorporate the cost of coverage for these other uses into its baseline estimates for Medicare spending, which means that the incremental cost of changing the law to allow Medicare coverage for anti-obesity drugs would be lower than it would be without FDAs approval of these drugs for other uses
Serious Health Concerns: While rare, GLP1's can lead to severe conditions like acute pancreatitis, acute kidney injury, and gallbladder disease
Currently, the standard of care does not include injecting or prescribing unapproved experimental peptides for injuries there is no FDA approval or authoritative guideline endorsing BPC-157 use
During this period, your focus will be on consistently taking your medication and observing how your body responds
Your provider may prescribe glutathione pills to prolong the effects of glutathione injectables